If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Mounjaro ® (tirzepatide) injection
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Is Mounjaro® (tirzepatide) indicated for patients with type 1 diabetes?
Tirzepatide has not been studied in people with type 1 diabetes.
See important safety information, including boxed warning, in the attached prescribing information.
Use in Patients With Type 1 Diabetes
Enclosed Prescribing Information
1Mounjaro [package insert]. Indianapolis, IN: Eli Lilly and Company; 2023.
2Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: March 02, 2023